Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement is part of MediWound's global commercialization strategy that will expand the medical and commercial potential of NexoBrid to treat skin burns.
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MediWound
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 02, 2020